Geneos Therapeutics today announced that it has secured $5 million in its Series A3 round.
-- Proceeds to Fund Expansion of Phase 1b/2a Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer -- -- Financing adds 3B Future Health Fund to Investor Syndicate and Dr. Roberto DePonti as Board Observer -- PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- GeneOS, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has secured $5 million in its Series A3 round. This financing adds 3B Future Health Fund (3B FHF) to Geneos’ investor syndicate. Further, Dr. Roberto DePonti, managing director and general partner of 3B FHF, joins Geneos as a board observer, adding decades of pharmaceutical drug development experience to the company. Proceeds Will Fund Expansion of Phase 1b/2a GT-30 Program “We are excited to contribute to the development of Geneos’ advanced approach to treat, patients with HCC as well as multiple additional types of cancer in the future,” stated Riccardo Braglia, general partner of 3B Future Health Fund II. “We are encouraged by the very promising results in the current clinical trial and look forward to working closely with the talented Geneos team.” “We are delighted to welcome Roberto and 3B FHF into our investor syndicate. We look forward to working with 3B FHF and their strong worldwide pharmaceutical development expertise and broad network in advancing our novel personalized therapeutic cancer vaccines,” stated Niranjan Sardesai, PhD., president and chief executive officer of Geneos Therapeutics. About 3B Future Health Fund II About Geneos Therapeutics This press release contains certain forward-looking statements relating to our business, including our plans regarding the development of personalized therapeutic cancer vaccines, our expectations regarding our research and development programs, including the planned expansion and conduct of clinical trials and the availability and timing of data from those trials, and the use of our capital resources. Actual events or results may differ from the expectations set forth herein. There can be no assurance that any product candidate in Geneos’ pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Geneos undertakes no obligation to update or revise these statements, except as may be required by law. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. View original content:https://www.prnewswire.com/news-releases/geneos-therapeutics-secures-5-million-in-series-a3-financing-301795107.html SOURCE Geneos Therapeutics, Inc. |